The process of evaluation, speculation or predicting the future of stocks in the biopharmaceutical sector is quite a challenge, as a large part of its success depends on drugs that are still in the pipeline. Such speculations are often vague, since it can take several years for such businesses to run profits. Celgene (NASDAQ:CELG), is quite a popular and trusted name in the biopharmaceutical industry, for quite a while.

Celgene (NASDAQ:CELG) is classed as elite amongst fellow firms, it has several effective medicinal products and promises more innovative drug existence in its pipeline. This approach has helped them gain a huge market share and catered to their success in the stock market. But the question that arises now is what exactly does Celgene (NASDAQ:CELG) have in its development pipeline. Celgene (NASDAQ:CELG) has over 50 clinical studies, currently. Most of these are experimental drugs, under review by Food and Drug Administration. A total of 18 are in early stage of testing, 17 are at mid-level and 13 are at its final stages. Another 6 drugs have been sent for FDA review and approval.

The drug development pipeline is important as new and innovative experimental drugs should never fall short. For Celgene (NASDAQ:CELG), there hasn’t been a problem, but in the future; it seem Revlimid might need to be replaced. Revlimid, is a drug, used to treat anemia; caused by myelodysplastic syndrome and other types of blood cancer. This drug, up till now, makes 66% of Celgene (NASDAQ:CELG)’s $1.85 billion in net sales. But future forecasts indicate that by 2017, Revlimid will only be able to generate half of the revenue it does now. Hence Celegene has already started looking into the matter for replacements.

According to the new results that emerged through intensive research, there is a possibility that Revlimid might survive in the market well beyond 2019. Currently, it is being tested for other medical conditions, such as:

-          First line and maintenance therapy to diffuse large B cell in lymphoma

-          First stages of follicular lymphoma

-          Relapsed indolen lymphoma treatment

-          For chronic lymphocytic leukemia maintenance therapy

If Revlimid gets approval, it could cater for atleast $1 bilion in annual sales for the company, and result in on-going success of the product. Revlimid is also under study at other geographical locations like Japan and EU, to use for T-cell leukemia and lymphoma and relapsed mantle cell lymphoma. With all these pieces put together, Revlimid might become a giant drug.

Another approach that will be fruitful for the company, in the long run is the anti-inflammatory drug Otezla, used by arthritis patients. Rheumatoid arthritis is quite profitable in terms of sales and is the second largest treatment in the market for arthritis, a very common condition.

At this stage, the combination of its existing drug, and label expansion  of existing drug with development of new products are all working in favor of Celgene (NASDAQ:CELG). The company continues to attract investors to its doorstep.

Get Free Updates and Stock Alerts!

*We only send one email per week